ABMD - Abiomed ticks higher after HSR waiting period for Johnson & Johnson sale expires
- Abiomed ( NASDAQ: ABMD ) ticked up 1% in premarket trading after the antitrust waiting period for its sale to Johnson & Johnson ( NYSE: JNJ ) expired.
- The required waiting period under the HSR act expired on Wednesday, according to a regulatory filing.
- Johnson & Johnson ( JNJ ) agreed to buy Abiomed ( ABMD ) early last month in a deal valued at ~$16.6B, including debt and cash, or $380 a share in cash initially.
For further details see:
Abiomed ticks higher after HSR waiting period for Johnson & Johnson sale expires